7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Heart Failure D006333 36 associated lipids
Arthritis, Rheumatoid D001172 3 associated lipids
Osteitis D010000 10 associated lipids
Coronary Disease D003327 70 associated lipids
Prostatic Neoplasms D011471 126 associated lipids
Osteosarcoma D012516 50 associated lipids
Hip Fractures D006620 2 associated lipids
Osteolysis D010014 8 associated lipids
Hypothyroidism D007037 32 associated lipids
Osteoarthritis, Hip D015207 4 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Middleton K et al. Microfluidic co-culture platform for investigating osteocyte-osteoclast signalling during fluid shear stress mechanostimulation. 2017 J Biomech pmid:28552413
Liu XY et al. Protective effects of total flavonoids of Astragalus against adjuvant-induced arthritis in rats by regulating OPG/RANKL/NF-κB pathway. 2017 Int. Immunopharmacol. pmid:28092862
Ozaki Y et al. Treatment of OPG-deficient mice with WP9QY, a RANKL-binding peptide, recovers alveolar bone loss by suppressing osteoclastogenesis and enhancing osteoblastogenesis. 2017 PLoS ONE pmid:28937990
Tschiderer L et al. Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based meta-analysis involving 26,442 participants. 2017 PLoS ONE pmid:28837646
Shu R et al. Sclerostin Promotes Bone Remodeling in the Process of Tooth Movement. 2017 PLoS ONE pmid:28081119
Ji J et al. Pathway of 3-MCPD-induced apoptosis in human embryonic kidney cells. 2017 J Toxicol Sci pmid:28070108
Sponder M et al. Endurance training significantly increases serum endocan but not osteoprotegerin levels: a prospective observational study. 2017 BMC Cardiovasc Disord pmid:28056805
Hygum K et al. MECHANISMS IN ENDOCRINOLOGY: Diabetes mellitus, a state of low bone turnover - a systematic review and meta-analysis. 2017 Eur. J. Endocrinol. pmid:28049653
Dawson S and Lawrie A From bones to blood pressure, developing novel biologic approaches targeting the osteoprotegein pathway for pulmonary vascular disease. 2017 Pharmacol. Ther. pmid:27373854
Yu M et al. Chemotherapy effectively suppresses interleukin-20, receptor activator of nuclear factor kappa-B ligand, and osteoprotegerin levels in patients with lung adenocarcinoma and bone metastasis. 2016 Apr-Jun J Cancer Res Ther pmid:27461682

Table of Content